Cancer Genetics Inc. [NASDAQ: CGIX] gained 37.14% or 1.3 points to close at $4.80 with a heavy trading volume of 3620343 shares. The company report on January 29, 2021 that SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Waddell & Reed Financial, Inc. (NYSE:WDR) relating to its proposed sale to Macquarie Asset Management. (“Macquarie”). Under the terms of the agreement, WDR shareholders are expected to receive $25.00 per share. Click here for more information: https://www.monteverdelaw.com/case/waddell-reed-financial-inc. It is free and there is no cost or obligation to you.
It opened the trading session at $3.85, the shares rose to $4.80 and dropped to $3.51, the range by which the price of stock traded the whole day. The daily chart for CGIX points out that the company has recorded 62.16% gains over the past six months. However, it is still -150.0% lower than its most recent low trading price.
If we look at the average trading volume of 708.95K shares, CGIX reached to a volume of 3620343 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Cancer Genetics Inc. [CGIX]:
Maxim Group have made an estimate for Cancer Genetics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 07, 2017. The new note on the price target was released on June 27, 2017, representing the official price target for Cancer Genetics Inc. stock. Previously, the target price had yet another raise to $6, while The Benchmark Company analysts kept a Speculative Buy rating on CGIX stock.
The Average True Range (ATR) for Cancer Genetics Inc. is set at 0.55, with the Price to Sales ratio for CGIX stock in the period of the last 12 months amounting to 3.18. The Price to Book ratio for the last quarter was 2.33, with the Price to Cash per share for the same quarter was set at 0.26.
Trading performance analysis for CGIX stock
Cancer Genetics Inc. [CGIX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.63. With this latest performance, CGIX shares gained by 77.12% in over the last four-week period, additionally plugging by 62.16% over the last 6 months – not to mention a rise of 11.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CGIX stock in for the last two-week period is set at 62.06, with the RSI for the last a single of trading hit 62.95, and the three-weeks RSI is set at 61.11 for Cancer Genetics Inc. [CGIX]. The present Moving Average for the last 50 days of trading for this stock 2.95, while it was recorded at 4.08 for the last single week of trading, and 3.32 for the last 200 days.
Cancer Genetics Inc. [CGIX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Cancer Genetics Inc. [CGIX] shares currently have an operating margin of -37.14 and a Gross Margin at +49.34. Cancer Genetics Inc.’s Net Margin is presently recorded at -94.25.
Return on Total Capital for CGIX is now -18.71, given the latest momentum, and Return on Invested Capital for the company is -92.20. Return on Equity for this stock declined to -97.06, with Return on Assets sitting at -27.37. When it comes to the capital structure of this company, Cancer Genetics Inc. [CGIX] has a Total Debt to Total Equity ratio set at 33.49. Additionally, CGIX Total Debt to Total Capital is recorded at 25.09, with Total Debt to Total Assets ending up at 16.59. Long-Term Debt to Equity for the company is recorded at 5.00, with the Long-Term Debt to Total Capital now at 3.74.
Reflecting on the efficiency of the workforce at the company, Cancer Genetics Inc. [CGIX] managed to generate an average of -$62,591 per employee. Receivables Turnover for the company is 1.89 with a Total Asset Turnover recorded at a value of 0.29.Cancer Genetics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.60.
Cancer Genetics Inc. [CGIX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Cancer Genetics Inc. posted -4.8/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -3,592.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CGIX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cancer Genetics Inc. go to 40.00%.
An analysis of insider ownership at Cancer Genetics Inc. [CGIX]
There are presently around $1 million, or 16.90% of CGIX stock, in the hands of institutional investors. The top three institutional holders of CGIX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 193,401, which is approximately 11.47% of the company’s market cap and around 7.49% of the total institutional ownership; BLACKROCK INC., holding 36,665 shares of the stock with an approximate value of $0.13 million in CGIX stocks shares; and COUNTRY CLUB TRUST COMPANY, N.A., currently with $70000.0 in CGIX stock with ownership of nearly New of the company’s market capitalization.
Positions in Cancer Genetics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 5 institutional holders increased their position in Cancer Genetics Inc. [NASDAQ:CGIX] by around 54,877 shares. Additionally, 6 investors decreased positions by around 4,042 shares, while 3 investors held positions by with 221,203 shares. The mentioned changes placed institutional holdings at 280,122 shares, according to the latest SEC report filing. CGIX stock had 2 new institutional investments in for a total of 20,037 shares, while 3 institutional investors sold positions of 1,137 shares during the same period.